Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • DISMAL report: Fortis...

    DISMAL report: Fortis reports net loss for Sept, Dec quarters

    Written by Ruby Khatun Khatun Published On 2018-03-02T09:44:39+05:30  |  Updated On 2 March 2018 9:44 AM IST
    DISMAL report: Fortis reports net loss for Sept, Dec quarters

    New Delhi: Fortis Healthcare reported a consolidated net loss of Rs 19.10 crore for the quarter ended December 2017 against a profit of Rs 453.29 crore in the year-ago period.


    The company also reported its September quarter net loss at Rs 23.61 crore after it had sought a 15-day extension to declare earnings for the second and third quarter of the current financial year citing statutory auditors' inability to complete the audit before the stipulated board meeting.


    Read also: Fortis Healthcare seeks 15-day extension to declare Q2, Q3 results

    Although the company presented its earnings report, the auditor to Fortis Healthcare, Deloitte Haskins & Sells LLP, said it had not performed an audit.


    It said the interim results have been reviewed by other auditors whose report has been furnished to them by the management.


    "Because of the significance of the matters... relating to the ongoing investigations... we were not able to obtain sufficient appropriate evidence to form a conclusion on the statement," it added.


    The results of Fortis Healthcare come amid controversy and scrutiny of the company's finances over alleged regulatory lapses in the transfer of funds to some promoter-linked firms.


    In an early morning regulatory filing, the company presented its earnings for the second and third quarter of the ongoing fiscal.


    Total income during the December quarter stood at Rs 1,163.27 crore. It was Rs 1,192.31 crore in the same quarter previous fiscal.


    For the quarter ended September 2017, income was reported at Rs 1,234.25 crore.


    Meanwhile, shares of the company were trading flat at Rs 159.75 apiece on BSE.


    Fortis Healthcare landed into trouble after a media report claiming that the company's promoters, Malvinder Mohan Singh and Shivinder Mohan Singh, took at least USD 78 million (about Rs 500 crore at current exchange rate) out of the publicly-traded hospital company they control without board approval about a year ago.


    Read also: Singh brothers took 78 million dollars out of Fortis: Report

    The company said its wholly-owned arm Fortis Hospitals had deployed funds to the tune of Rs 473 crore as secured short-term investments to group firms of its promoters.


    Read also: Fortis Healthcare justifies Rs 473 crore to ex-directors, says money secure

    The move attracted regulatory scrutiny as Sebi began examining the issues following the resignation of the two promoters from the board.


    Read also: Sebi says looking into Fortis Healthcare matter


    The company said the loans are adequately secured and repayment has since commenced as per agreed payment schedule.


    The company's statutory auditor said Sebi is conducting an investigation in respect of secured short-term investment of Rs 473 crore made by the wholly-owned subsidiary of the parent, and pending completion of the investigation, it is unable to "conclude on effects, if any of the outcome of the same on the financial results, state of affairs, cash flows, and operations of the group".

    December quarterFinancial resultsFortisFortis HealthcareFortis HospitalsMalvinder Mohan Singhnet lossSeptember quarterShivinder Mohan Singh
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok